Skip to main content
. 2021 Apr 29;13(9):2155. doi: 10.3390/cancers13092155

Figure 3.

Figure 3

Freedom from progression (FFP). Kaplan–Meier curves for freedom from progression, stratified by diagnostic CIP2A level for (a) all 172 patients, (b) imatinib recipients, and (c) dasatinib recipients. p-values were determined using the log-rank (Mantel–Cox) test; p-values are shown where significant.